follow
malign
tumor
group
basi
histogenesi
histolog
type
differenti
howev
tumor
group
may
heterogen
although
histopatholog
partli
abl
predict
clinic
behavior
still
play
domin
role
select
patient
manag
improv
situat
molecular
approach
becom
part
diagnost
process
hope
ad
inform
convent
morpholog
abl
provid
predict
clinic
behavior
individu
tumor
push
challeng
patholog
clinician
strongli
demand
reliabl
predict
regard
prognosi
metastat
potenti
andor
respons
therapi
appli
dna
array
sever
approach
perform
success
improv
predict
accuraci
recent
year
effort
devot
unravel
potenti
new
therapeut
target
lead
develop
new
drug
exampl
herceptin
gleevec
first
design
drug
use
consider
success
clinic
basi
develop
provid
tissuebas
investig
perform
experiment
pathologist
bernd
groner
georg
speyer
hau
inst
biomed
research
frankfurt
present
data
novel
approach
target
tumor
therapi
inappropri
assembl
modular
compon
play
role
oncogen
transform
diseas
exploit
therapeut
purpos
target
structur
howev
convent
consid
druggabl
interact
mediat
surfac
structur
fold
protein
peptid
embed
context
scaffold
protein
serv
competit
inhibitor
protein
recognit
modul
peptid
aptam
target
noncanon
drug
bind
site
disrupt
intracellular
protein
function
applic
principl
depend
upon
bind
specif
affin
peptid
aptam
target
structur
recombin
express
purif
peptid
aptamerscaffold
protein
deliveri
purifi
protein
cell
improv
upon
scaffold
structur
util
human
thioredoxin
molecul
remov
five
intern
cystein
allow
purif
monomer
protein
high
yield
provis
molecul
protein
transduct
domain
consist
nine
arginin
result
fusion
protein
taken
effici
cultur
cell
inhibit
intracellular
signal
function
associ
cellular
phenotyp
peptid
aptam
recogn
intracellular
part
receptor
introduc
breast
cancer
cell
reduc
extent
akt
kinas
induct
upon
heregulin
treatment
cell
enhanc
resist
toward
chemotherapeut
agent
overexpress
cancer
cell
peptid
aptam
direct
dimer
domain
transcript
factor
prevent
transactiv
induc
growth
inhibit
induct
apoptosi
christian
hagemei
children
hospit
lab
molecular
biolog
berlin
spoke
molecular
approach
understand
tackl
acut
lymphoblast
leukemia
children
probabl
longterm
surviv
relaps
acut
lymphoblast
leukemia
predict
wellestablish
prognost
mainli
clinic
factor
howev
underli
biolog
determin
prognost
factor
poorli
understood
collabor
depart
pediatr
oncolog
hous
bfm
allrez
studi
group
defin
molecular
prognost
marker
risk
stratif
identifi
gene
express
program
character
pathogenesi
patient
poor
outcom
search
gene
modul
therapeut
approach
found
earli
onset
relaps
typic
associ
particularli
low
eventfre
surviv
rate
distinguish
late
diseas
recurr
increas
prolif
capac
leukem
blast
distinct
express
gene
function
cell
cycl
control
particularli
process
mitosi
addit
employ
genet
shrna
screen
identifi
set
gene
modul
therapeut
approach
cell
culturebas
model
implic
discuss
per
sonn
holm
inst
experiment
oncolog
research
technic
univers
munich
report
target
develop
oncolyt
adenoviru
shown
regul
express
number
gene
link
cell
prolifer
growth
addit
multifunct
protein
involv
regul
translat
mrna
splice
dna
repair
indic
involv
control
cell
surviv
recent
year
sever
laboratori
demonstr
respons
genotox
stress
like
chemotherapi
transloc
cytoplasm
nucleu
besid
transcript
activ
human
gene
nuclear
local
transcript
factor
associ
base
excis
mismatch
repair
pathway
bind
sever
dna
repair
protein
found
amongst
other
highli
overexpress
mani
malign
current
result
suggest
import
confer
eg
drug
resist
mani
type
tumor
cell
oncolyt
adenovirus
attract
consider
attent
use
innov
class
promis
cancer
therapeut
develop
sever
oncolyt
adenovir
vector
replic
presenc
tumor
cell
applic
oncolyt
vector
produc
strong
antitumor
effect
sever
carcinoma
cell
line
applic
vivo
subcutan
establish
tumor
led
strong
tumor
growth
inhibit
could
enhanc
radiat
chemotherapi
conclus
adenovirus
highli
effect
differ
malign
deserv
clinic
test
reinhold
inst
patholog
berlin
explain
oncogen
ra
signal
effector
pathway
target
regul
interfer
hundr
transcript
target
upregul
downregul
transit
normal
rastransform
state
minor
target
equal
deregul
differ
cell
type
indic
exist
limit
number
common
ra
pathway
target
set
upregul
gene
compris
factor
involv
growth
control
invas
metastasi
mani
downregul
gene
encod
protein
antiprolif
antiinvas
antiangiogen
properti
involv
deregul
gene
trigger
execut
variou
aspect
malign
transform
unknown
moreov
global
mechan
control
express
yet
understood
unravel
regulatori
mechan
perturb
transcript
network
downstream
ra
signal
cascad
find
target
primarili
involv
tumorigenesi
employ
sever
experiment
strategi
narrow
number
critic
target
correl
effect
block
individu
effector
pathway
use
pharmacolog
inhibitor
rna
interfer
transcript
pattern
specif
phenotyp
select
target
exhibit
signific
differenti
express
rastransform
vs
normal
cell
rna
interfer
experi
studi
role
dna
methyl
target
gene
suppress
subject
rastransform
cell
treatment
demethyl
agent
determin
fraction
respond
target
exampl
shown
clusterin
gene
suppress
control
promot
methyl
mapkpathway
suggest
dynam
relationship
ra
signal
dna
methyl
unravel
relationship
effector
pathway
transcript
network
provid
import
clue
understand
system
biolog
cancer
help
identifi
novel
biomark
eventu
specif
node
therapeut
intervent
xuetao
cao
inst
immunolog
nation
key
laboratori
medic
immunolog
smmu
shanghai
gave
report
nuclear
entrap
oncogen
rasrel
gtpbind
protein
promot
tumor
progress
tumorigenesi
wide
recogn
intric
multistep
process
involv
malfunct
protooncogen
tumor
suppressor
gene
key
cellular
gene
implic
cell
prolifer
differenti
surviv
genom
integr
malfunct
protooncogen
signal
compon
report
among
rasrafmek
mitogenactiv
protein
kinas
mapk
erk
kinas
erk
extracellular
signalregul
kinas
signal
compon
identifi
play
import
role
tumorigenesi
cytoplasm
protein
contain
nuclear
export
signal
ne
play
crucial
role
determin
cell
growth
differenti
activ
extracellular
signalregul
kinas
rjl
famili
rasrel
gtpbind
protein
character
ntermin
gtpbind
domain
small
gtpase
domain
ctermin
j
domain
unknown
function
fulllength
human
rjl
hrjl
cdna
identifi
us
via
largescal
sequenc
human
peripher
blood
monocytederiv
dendrit
cell
cdna
librari
report
hrjl
nucleusloc
repres
rjl
famili
mediat
accumul
activ
nucleu
mask
ne
turn
result
constitut
activ
malign
transform
show
hrjl
overexpress
tumor
cell
tumor
tissu
oncogen
vitro
vivo
silenc
hrjl
express
disrupt
interact
result
regress
tumor
growth
metastasi
find
suggest
hrjlmediat
nuclear
entrap
play
import
role
promot
autonom
tumor
progress
hrjl
novel
oncogen
therapeut
target
guoqiang
chen
dept
pathophysiolog
shanghai
jiao
tong
univers
school
medicin
report
hypoxia
leukem
cell
differenti
evid
vitro
vivo
state
cobalt
chlorid
desferrioxaminemimick
hypoxia
moder
hypoxia
trigger
acut
myeloid
leukemia
aml
cell
undergo
differenti
intermitt
hypoxia
significantli
prolong
surviv
transplant
leukem
mice
induc
growth
arrest
differenti
inhibit
leukem
blast
infiltr
base
vitro
vivo
observ
explor
role
hypoxiainduc
factor
protein
leukem
cell
differenti
result
show
condit
induct
trigger
granulocyt
differenti
myeloid
leukem
transform
tightli
induc
tetracyclin
withdraw
suppress
express
essenti
partner
transcript
activ
specif
short
hairpin
rna
shrna
effect
inhibit
hypoxiainduc
differenti
cell
inhibit
hematopoiet
differentiationcrit
ccaatenhanc
bind
proteinalpha
cebpa
significantli
elimin
myeloid
leukem
cell
differenti
furthermor
also
shown
interact
physic
increas
transcript
activ
cebpa
two
critic
factor
granulocyt
differenti
collect
work
provid
sever
line
direct
evid
role
protein
nontranscript
activ
myeloid
cell
differenti
cebpa
elicit
role
effector
downstream
discoveri
would
shed
new
insight
understand
mechan
underli
leukemogenesi
design
new
therapeut
strategi
differenti
induct
aml
jing
cheng
medic
system
biolog
research
center
tsinghua
univers
school
medicin
haidian
district
beij
explain
diagnost
biochip
research
consum
market
biochipbas
platform
research
develop
rapidli
past
decad
includ
chip
gener
detail
biolog
inform
four
differ
gene
protein
cell
tissu
level
exampl
gene
level
snp
mutat
analysi
microarray
compar
genom
hybrid
microarray
methyl
detect
microarray
mrna
mirna
express
profil
microarray
protein
level
establish
activ
transcript
factor
profil
chip
well
chipglasbas
promot
chip
cellular
level
chip
singl
cell
ion
flux
monitor
multichannel
electrophysiolog
measur
cell
network
final
patholog
examin
provid
numer
differ
tissu
microarray
includ
normal
diseas
tissu
recent
year
demand
gener
consumpt
new
class
biochip
keenli
anticip
consum
area
diseas
diagnost
biosafeti
test
etc
furthermor
present
differ
type
consum
biochip
product
introduc
includ
dna
microarray
detect
presenc
sar
corona
viru
rna
detect
gramposit
bacteria
associ
drug
resist
gene
detect
mycobacterium
drug
resist
gene
tb
detect
foodborn
pathogen
protein
microarray
diagnosi
autoimmun
diseas
detect
veterinari
drug
residu
antibiot
broad
rang
applic
biochip
foreshadow
futur
develop
wider
rang
sensit
test
product
jianren
gu
state
key
lab
oncogen
relat
gene
shanghai
cancer
institut
jiao
tong
univers
discuss
conceptu
concern
cancer
biolog
major
problem
cancer
treatment
cancer
cluster
cancer
cell
wellorgan
tissuecanc
cell
heterogen
among
cancer
cell
popul
cancer
stem
cell
may
crucial
target
treatmentdissemin
may
earli
event
type
cancer
also
differ
event
metastasi
mechan
evok
growth
dissemin
cancer
cell
metastat
lesion
crucial
develop
new
therapeut
method
control
cancercanc
could
system
diseas
local
manifest
abnorm
cell
growth
develop
basi
deregul
hostcel
homeostasi
includ
neural
humor
immun
mechan
conceptu
consider
may
provid
clue
explor
mechan
carcinogenesi
cancer
progress
well
design
new
therapeut
strategi
cancer
yajun
guo
intern
joint
cancer
institut
smmu
shanghai
yjguo
smmueducn
explain
topic
novel
vaccin
develop
cancer
immunotherapi
develop
sever
novel
bispecif
antibodi
consist
two
normal
bind
site
target
antigen
function
portion
construct
bispecif
antibodi
effici
target
hepatoma
breast
lymphoma
cancer
cell
vitro
vivo
lead
accumul
dc
nk
cell
lymphocyt
local
tumor
tissu
administr
bispecif
monoclon
antibodi
protect
bone
marrow
injuri
caus
chemotherapeut
drug
stimul
prolifer
matur
lymphocyt
apc
nk
system
administr
bispecif
antibodi
inject
significantli
inhibit
tumor
growth
cure
establish
tumor
bispecif
therapeut
protein
effect
elicit
longlast
antitumor
immun
tumorspecif
immun
adopt
transfer
anim
success
transfus
cell
treat
mice
result
suggest
fusion
therapeut
antibodi
creat
novel
immunotherapeut
protein
effect
induct
antitumor
immun
may
provid
novel
strategi
treatment
cancer
yongfeng
shang
peke
univers
talk
gene
regul
nuclear
receptor
steroid
receptor
coactiv
src
exert
profound
effect
anim
develop
physiolog
coactiv
nuclear
protein
transcript
coregul
function
facilit
transcript
initi
mediat
nuclear
receptor
well
wellknown
transcript
factor
howev
coregul
function
regul
poorli
understood
genomewid
screen
srcinteract
protein
identifi
novel
ankyrinrepeatcontain
protein
srcinteract
protein
sip
interact
src
coactiv
cytoplasm
demonstr
extracellular
stimuli
addit
estrogen
induc
phosphoryl
sip
pest
prolin
glutam
serin
threoninerich
domain
casein
kinas
ii
phosphoryl
sip
result
dissoci
src
protein
sip
cytoplasm
led
subsequ
nuclear
transloc
src
protein
gene
coactiv
gainoffunct
lossoffunct
experi
indic
sip
function
sequest
src
coactiv
cytoplasm
buffer
avail
coactiv
thu
provid
mechan
regul
transcript
regul
hongyang
wang
inst
intern
cooper
laboratori
signal
transduct
eastern
hepatobiliari
surgeri
institutehospit
shanghai
smmu
neg
regul
hepatocellular
carcinoma
cell
growth
signal
regulatori
protein
member
signal
regulatori
protein
sirp
famili
undergo
tyrosin
phosphoryl
bind
tyrosin
phosphatas
respons
variou
mitogen
express
level
decreas
human
hepatocellular
carcinoma
hcc
tissu
compar
match
normal
tissu
exogen
express
wildtyp
mutant
lack
tyrosin
phosphoryl
site
neg
human
hcc
cell
result
suppress
tumor
cell
growth
vitro
vivo
treatment
transfect
egf
hgf
induc
tyrosin
phosphoryl
associ
accompani
reduc
activ
express
significantli
suppress
activ
also
sensit
cell
cisplatininduc
cell
death
addit
cell
display
reduc
cell
migrat
cell
spread
fashion
depend
complex
format
conclus
result
suggest
neg
regulatori
effect
hepatocarcinogenesi
least
part
inhibit
erk
pathway
heighten
sensit
cell
restor
function
could
exploit
develop
therapeut
regimen
may
potenti
antineoplast
effect
convent
cytokin
chemotherapeut
agent
qimin
zhan
cancer
institut
chines
academi
medic
scienc
explain
role
bacp
centrosom
protein
control
genom
stabil
essenc
success
mitosi
mammalian
cell
gener
two
genet
ident
daughter
cell
success
mitosi
requir
assembl
strictli
bipolar
mitot
apparatu
ensur
chromosom
equal
distribut
daughter
cell
process
control
centrosom
requir
spindl
format
function
centrosom
stabil
requir
success
mitosi
mammalian
cell
amplif
centrosom
lead
chromosom
missegreg
gener
aneuploidi
close
associ
cell
transform
tumorigenesi
machineri
control
centrosom
stabil
involv
multipl
import
cellular
protein
includ
e
precis
coordin
among
regul
maintain
centrosom
duplic
stabil
howev
current
limit
insight
mechan
critic
biolog
event
breast
cancer
suscept
gene
implic
control
mitot
machineri
although
littl
insight
underli
mechan
show
physic
interact
coloc
bacp
associ
centrosom
protein
interestingli
bacp
centrosom
local
like
depend
normal
cellular
function
cell
contain
mutat
silenc
endogen
reveal
disrupt
bacp
coloc
centrosom
suppress
endogen
bacp
result
aberr
spindl
format
failur
chromosom
segreg
cytokinesi
aneuploidi
bacp
overexpress
human
breast
lung
carcinoma
deregul
part
associ
bacp
amplif
bacp
exhibit
strong
oncogen
properti
induc
fibroblast
transform
importantli
bacp
transgen
mice
mimic
phenotyp
disrupt
includ
centrosom
amplif
spontan
tumorigenesi
thu
bacp
may
cooper
act
togeth
mitot
machineri
abnorm
bacp
lead
genom
instabl
tumorigenesi
jingd
zhu
cancer
epigenet
gene
therapi
program
shanghai
cancer
institut
cancer
epigenet
omic
dna
methyl
perspect
liver
cancer
paradigm
cancer
complex
diseas
broad
genet
epigenet
defect
epigenet
circuit
dictat
inherit
transcript
profil
therefor
phenotyp
better
understand
would
revolution
current
anticanc
practic
epigenet
makeup
compris
dna
methyl
histon
modif
microrna
chromatin
remodel
act
togeth
shape
chromatin
structur
genom
meet
function
requir
dna
methyl
enzymat
process
add
methyl
group
fifth
carbon
cytosin
within
palindrom
dinucleotid
sequenc
beststudi
pigenet
mechan
cancerassoci
aberr
dna
methyl
goe
two
opposit
direct
global
hypomethyl
local
hypermethyl
turn
dictat
transcript
profil
repetit
sequenc
individu
gene
therefor
phenotyp
profil
uniqu
cancer
state
hcc
present
major
health
threat
peopl
china
owe
high
incid
aggress
clinic
natur
current
carri
comprehens
profil
diseaseassoci
cpg
methyl
pattern
multipl
gene
level
global
level
gain
new
mechanist
insight
establish
dna
methylationbas
stage
classif
system
find
effect
biomark
hcc
demonstr
great
potenti
dna
methyl
cancer
detect
present
latest
result
dna
methyl
profil
urin
sediment
sensitivespecif
detect
bladder
cancer
